Tower Research Capital (TRC)’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-486
| Closed | -$9K | – | 4423 |
|
|
2018
Q1 | $9K | Sell |
486
-642
| -57% | -$12.6K | ﹤0.01% | 2523 |
|
|
2017
Q4 | $19K | Sell |
1,128
-3,042
| -73% | -$55.8K | ﹤0.01% | 2139 |
|
|
2017
Q3 | $85K | Buy |
+4,170
| New | +$79.7K | 0.01% | 1532 |
|
|
2016
Q3 | – | Sell |
-639
| Closed | -$18K | – | 5036 |
|
|
2016
Q2 | $18K | Sell |
639
-1,597
| -71% | -$52.1K | ﹤0.01% | 2355 |
|
|
2016
Q1 | $72K | Buy |
+2,236
| New | +$78.6K | 0.01% | 608 |
|
|
2015
Q4 | – | Sell |
-631
| Closed | -$22K | – | 5449 |
|
|
2015
Q3 | $22K | Buy |
+631
| New | +$28.4K | ﹤0.01% | 1667 |
|
|
2014
Q4 | – | Sell |
-201
| Closed | -$5K | – | 5109 |
|
|
2014
Q3 | $5K | Buy |
+201
| New | +$5.15K | ﹤0.01% | 3354 |
|
|
2014
Q2 | – | Sell |
-700
| Closed | -$18K | – | 4990 |
|
|
2014
Q1 | $18K | Buy |
+700
| New | +$17.5K | ﹤0.01% | 2031 |
|
|
2013
Q4 | – | Sell |
-657
| Closed | -$13K | – | 5178 |
|
|
2013
Q3 | $13K | Buy |
657
+357
| +119% | +$7.37K | ﹤0.01% | 3032 |
|
|
2013
Q2 | $6K | Buy |
+300
| New | +$5.33K | ﹤0.01% | 2865 |
|
Tower Research Capital (TRC)'s IPXL Position: Q2 2018 in Review
Tower Research Capital (TRC) sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 486 shares — an estimated $9K sold.
Tower Research Capital (TRC) first reported a position in IPXL in Q2 2013 and held it in 10 quarters. The position peaked at $85K in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Tower Research Capital (TRC) reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 486 Impax Laboratories, Inc. shares in Q2 2018, an estimated $9K.
- Tower Research Capital (TRC) first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 10 quarters.
- Tower Research Capital (TRC)'s Impax Laboratories, Inc. position peaked at $85K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2018, filed 15 Aug 2018.